Fruquintinib for refractory colorectal cancer in a pre-treated 82-year-old patient achieved a progression-free survival of 25 months: a case report

BACKGROUND: Chemotherapy was recommended as the 1(st) or 2(nd) line standard of care for patients with refractory or metastatic colorectal cancer (mCRC). Extra cautions are needed for elderly patients, because cytotoxic regimens may induce unexpected adverse effects due to their impaired physical co...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yi, Li, Jianjiong, Xu, Qiyang, Li, Kai, Zhang, Chen, Chen, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9660041/
https://www.ncbi.nlm.nih.gov/pubmed/36388671
http://dx.doi.org/10.21037/jgo-22-841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9660041/
https://www.ncbi.nlm.nih.gov/pubmed/36388671
http://dx.doi.org/10.21037/jgo-22-841

Ejemplares similares